Amylx Pharmaceuticals Inc vs ARK Next Generation Internet ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.6 (market cap $2.64B), while ARK Next Generation Internet ETF trades at $150.91. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, ARK Next Generation Internet ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | ARKW | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Sector/Thematic |
52-Week High | $24.19 | $182.20 |
52-Week Low | $7.82 | $114.45 |
Enterprise Value | $2.39B | — |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
ARKW trades at $150.88, up 0.87% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The ETF focuses on next-generation internet companies, though key financial ratios are not disclosed in the provided data. Recent news highlights long-term growth potential in AI and cloud infrastructure, balanced by near-term capital spending headwinds.
The outlook is mixed, with strong technical momentum but fundamental metrics unavailable for valuation. Risks include market skepticism on AI investments and sector volatility. Analyst sentiment is cautious, citing near-term challenges despite long-term positioning in transformative technologies.
Trailing returns across standard periods
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →ARKW is an actively managed ETF that invests in next-generation internet technologies. It focuses on cloud computing, AI, e-commerce, and blockchain innovation, with key holdings like Tesla, Advanced Micro Devices, and Roku.
Read more on ARKW →